Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
32.8K views | +2 today
Follow
Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Belimumab (Benlysta, HGSI, GSK) is the first new drug approved by the FDA during the last 50 years to treat Lupus or SLE. The EU expert panel has recommended its approval by the EMA. The EMA gave the MAA approval last friday.
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Belimumab (Benlysta, HGSI, GSK) Lupus Review - Krishan Maggon

Belimumab (Benlysta, HGSI, GSK) Lupus Review - Krishan Maggon | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
No new drug has been approved to treat Lupus during the past 50 years. Belimumab is one of the rare new biologics to complete Phase III trials with positive outcome. It has now been approved both in the US and EU.
more...
Gilbert C FAURE's comment, December 14, 2013 3:14 AM
nice ti illustrate with LBT
Scooped by Krishan Maggon
Scoop.it!

Stemness Maintenance Properties in Human Oral Stem Cells after Long-Term Passage

Stemness Maintenance Properties in Human Oral Stem Cells after Long-Term Passage | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Stem Cells International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of stem cell biology and applications. The journal will consider basic, translational, and clinical research, including animal models and...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A road map to stem cell development

A road map to stem cell development | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Johns Hopkins Medicine researchers report they have created a method of mapping how the central nervous system develops by tracking the genes expressed in cells. The technique, demonstrated in mouse retinas for this study, ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis | NEJM

Original Article from The New England Journal of Medicine — Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Parenchymal and stromal tissue regeneration of tooth organ by pivotal signals reinstated in decellularized matrix

Parenchymal and stromal tissue regeneration of tooth organ by pivotal signals reinstated in decellularized matrix | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
The Alx3 transcription factor, expressed in prenatal tooth development, is shown to revitalize adult progenitor cells in decellularized scaffolds, leading to enhanced parenchymal dental pulp and vascularized stroma regeneration in vivo.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

For The First Time, Scientists Have Linked Rare Genetic Mutations to Lupus

For The First Time, Scientists Have Linked Rare Genetic Mutations to Lupus | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
The autoimmune disorder lupus impacts roughly half a billion people worldwide, and yet while the name rings familiar, few among us know much about it. Now, we might be closer than ever to determining the real cause of this disease.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Human Induced Pluripotent Stem Cells -Angio-Proteomie

Human Induced Pluripotent Stem Cells -Angio-Proteomie | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Catalog NO: cAP-0500-001, Product Name: Human Induced Pluripotent Stem Cells, High Quality-Price Ratio Products and Services. Quality Assurance Guaranteed. Fast Worldwide Delivery Available.To Order: customerservice@angioproteomie.com, or, angioproteomie@gmail.com; Fax: 01-480-247-4337...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis | Annals of the Rheumatic Diseases

T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis | Annals of the Rheumatic Diseases | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Disease-associated clones showed common features and high similarity between both autoimmune diseases. SLE displayed higher TCR heterogeneity than RA with several organ specific properties. Furthermore, the association between clonal expansion and the concentration of disease-associated clones with disease severity were identified, and pathogen-related TCRs were enriched in both diseases.

Conclusions These characteristics of the TCR repertoire, particularly the disease-associated clones, can potentially serve as biomarkers and provide novel insights for disease status and therapeutical targets in autoimmune diseases.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The signaling adaptor BCAP inhibits NLRP3 and NLRC4 inflammasome activation in macrophages through interactions with Flightless-1 | Science Signaling

The signaling adaptor BCAP inhibits NLRP3 and NLRC4 inflammasome activation in macrophages through interactions with Flightless-1 | Science Signaling | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
BCAPing inflammasome activation
The PI3K adaptor protein BCAP limits cellular responses to TLR stimulation and IL-1β. Using proteomics analysis, Carpentier et al. showed that BCAP interacted with Flightless-1 and its binding partner leucine-rich repeat Flightless-1–interacting protein 2 (LRRFIP2), which promoted an association between BCAP and the inflammasome component NLRP3. In macrophages, BCAP reduced the abundance of active caspase-1, maturation of the cytokine IL-1β, and cell death after exposure to the toxin nigericin or bacterial infection. Kinetic analyses determined that BCAP delayed recruitment of pro–caspase-1 to intracellular inflammasome foci and loss of BCAP promoted bacterial clearance in mice. These data identify a distinct role for this PI3K adaptor in preventing excessive, potentially harmful activation of NLRP3 and NLRC4 inflammasomes.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Objectives To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Cells |  (Epi)genetic Modifications in Myogenic Stem Cells: From Novel Insights to Therapeutic Perspectives

Cells |  (Epi)genetic Modifications in Myogenic Stem Cells: From Novel Insights to Therapeutic Perspectives | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
The skeletal muscle is considered to be an ideal target for stem cell therapy as it has an inherent regenerative capacity. Upon injury, the satellite cells, muscle stem cells that reside under the basal lamina of the myofibres, start to differentiate in order to reconstitute the myofibres while...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Charting cellular identity during human in vitro β-cell differentiation

Charting cellular identity during human in vitro β-cell differentiation | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
We show that endocrine cells maintain their identity in culture in the absence of exogenous growth factors, and that changes in gene expression associated with in vivo β-cell maturation are recapitulated in vitro. We implement a scalable re-aggregation technique to deplete non-endocrine cells and identify CD49a (also known as ITGA1) as a surface marker of the β-cell population, which allows magnetic sorting to a purity of 80%. Finally, we use a high-resolution sequencing time course to characterize gene-expression dynamics during the induction of human pancreatic endocrine cells, from which we develop a lineage model of in vitro β-cell differentiation. This study provides a perspective on human stem-cell differentiation, and will guide future endeavours that focus on the differentiation of pancreatic islet cells, and their applications in regenerative medicine.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Stem Cell Proliferation Is Kept in Check by the Chromatin Regulators Kismet/CHD7/CHD8 and Trr/MLL3/4 - ScienceDirect

Stem Cell Proliferation Is Kept in Check by the Chromatin Regulators Kismet/CHD7/CHD8 and Trr/MLL3/4 - ScienceDirect | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Chromatin remodeling accompanies differentiation, however, its role in self-renewal is less well understood.We report that in Drosophila, the chromat…...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Fraunhofer IBMT at BIO 2019: Automation solutions for workflows in stem cell process engineering

Fraunhofer IBMT at BIO 2019: Automation solutions for workflows in stem cell process engineering | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
23. Mai 2019, 8:45 Forschungs- / Wissenstransfer, Kooperationen Fraunhofer IBMT at BIO 2019: Automation solutions for workflows in stem cell process engineering Application-specific high-throughput stem cell production processes revolutionize industrial new drug testing. For biotechnological and pharmaceutical companies, the development of cell culture automation using innovative materials is a promising approach to optimize existing processes. By customized material characteristics, expansion and/or differentiation of human stem cells (with focus on human induced pluripotent stem cells, hiPSCs) shall be positively influenced and automated solutions for the production for high-qualitative cells shall be developed. Meet Fraunhofer IBMT, an expert in automation solutions for workflows in stem cell process engineering at the BIO International in USA. These generated cells can then be used for the production of model systems for drug tests, toxicity studies or disease modelling, thus providing e. g., a major contribution to personalized medicine or the avoidance of animal experiments. It is a long way from the development and production of individualized drug tests in the laboratory to the use in pharmaceutical industry. The Fraunhofer Project Center for Stem Cell Process Engineering SPT, a cooperation of the Fraunhofer Institutes for Biomedical Engineering IBMT and Silicate Research ISC, aims to accelerate the process with new automated cell production processes and innovative materials. New therapeutics run through time-consuming and labor-intensive procedures until they are put to use. Study results from cell culture screenings, mostly of animal origin, can often not be safely transferred to humans in terms of efficacy. More reliable are test systems based on human stem cells, which simulate corresponding organs. The so-called „induced pluripotent stem cells (iPSCs)“ nowadays make it possible to produce almost any and ethically unproblematic generation of embryonic-like stem cells from almost any body cell through genetic „reprogramming“. Although various university groups and initiatives already use these iPS cells for the development of cellular therapy approaches, the industrial relevance is very low due to high costs up to the therapy product, long development times and strict necessary regulations. The translation of research results to industrial use is pushed by the Fraunhofer Project Center for Stem Cell Process Engineering SPT. High quality stem cells in large numbers and best quality Improved disease models and new therapeutic approaches require cells in high numbers and quality. The production and packaging of high-quality stem cells and derived cells lacks broadly functioning, highly scaled and validated bioprocessing techniques. Also, there is a lack of specifically adapted materials as bioactive surfaces or scaffolds for 2D and 3D culture as well as automated techniques for high-throughput cell screening. Another aspect of the future is the structuring of the resulting microscopic data for later Big Data applications. The Project Center for Stem Cell Process Engineering offers the competence in the establishment of biomedical workflows in the field of iPSCs (stem cell technologies, automation of cellular workflows, such as expansion, differentiation and screening, new read-out methods, cryopreservation and biobanking) of the Fraunhofer IBMT as well as the material science competence (bioactive materials and surface functionalizations) of the Fraunhofer ISC. The Fraunhofer IBMT has been working successfully in the field of iPSC research for more than ten years and possesses substantial know-how for the scaling up of cell culture and for the development of efficient differentiation processes. It was the first and only institute of the Fraunhofer Gesellschaft to obtain authorizations of the Robert Koch Institute for the import and scientific use of human embryonic stem cells (No. 18, 19 and 44). In recent years, the production and characterization/ expansion of induced pluripotent stem cells have been added. For more than 10 years, it has been working on European projects on applied research with pluripotent stem cells and is involved in setting up an international iPS cell bank as part of a major European project in which it manages the German mirror of this cell bank (EBiSC + EBiSC2). Focus on integrated and specific technology development for stem cells „The project center thus offers an integrated portfolio for the development of application-specific high-throughput production processes for stem cell applications,“ says Professor Zimmermann, Head of Institute of Fraunhofer IBMT and Managing Director of the Fraunhofer Project Center SPT. The project center creates a unique combination of research and development in Europe for bioreactors, tissue engineering scaffolds and novel, autonomous cell production. The aim is to create standardized production processes for stem cell cultures that can be individually adapted and specified depending on the field of application for drug research in order to shorten the time to market in the development pipeline of the pharmaceutical and biotech industries. Further Information about the Fraunhofer-Institute for Biomedical Engineering „Translation from Research to Commercialization“ Business Areas: Medical Engineering, Theranostics, Laboratory Technology Competences:  Stem Cells (Project Center for Stem Cell Process Engineering Würzburg, Cell Culture Automation, Materials, Biomedical Data Sciences, European Bank for induced Pluripotent Stem Cells EBiSC + EBiSC2)  Medical Biotechnology (Biobanking, Automation Processes, Cryotechnology, Clinical Stem Cell Technologies, Cellular Bioprocessing, Nanotechnology, Pre-clinical Nanomedicine)  Ultrasound (Biomedical, Technical, Sonar)  Biomedical Engineering (Microsensors, Biotelemetry, Active Implants, Neuroprosthetics & Neuromonitoring, Health Information Systems) Operating in the international growth markets for life sciences and medicine/ (bio)medical engineering since its foundation in 1987/1992, the Fraunhofer Institute for Biomedical Engineering IBMT has worked primarily as a technology developer and device manufacturer for customers from all over the world. As a founding member of the Life Sciences Group of the Fraunhofer Gesellschaft, the Fraunhofer IBMT cooperates closely with its industrial customers as well as public and private customers in the business areas of laboratory technology, theranostics and medical engineering. The IBMT’s strategy is focused on the areas of biomedical/medical engineering (especially non-invasive and minimally invasive as well as miniaturized technologies), biotechnology, implants, cryotechnology, biobanks and stem cell research. Trend-setting automated laboratory technologies, the development of mobile special laboratories (S3, GMP, GCLP, etc.) and information technologies for healthcare solutions round off the portfolio of the Fraunhofer IBMT. Decades of expertise in biotechnological and medical research and development fields also allows us to solve a variety of purely technical tasks. This includes ultrasound-based level metering, special transducers for acoustic applications, sonars, but also microelectrodes and miniaturized manipulation systems as well as automated in vitro culture devices. With a good balance between basic and applied research, the institute promotes the „lived“ technology transfer in medicine and biotechnology, laboratory technology, food, chemical and pharmaceutical industries and environmental technology as well as in other areas of industry and knowledge-intensive services. For many years, the Fraunhofer IBMT successfully has been working in the field of stem cell research and has been the first institute of the Fraunhofer Gesellschaft to obtain licences (No. 18, 19 and 44) of the Robert Koch Institute to import and use human embryonic stem cells for scientific purposes. In recent years this has been extended to the production and characterization/expansion of induced pluripotent stem cells (iPSCs). The institute is involved as part of a major European project in building an international iPS cell bank EBiSC + EBiSC2). Core competencies of the Fraunhofer IBMT are: • biomedical/medical engineering • molecular and cellular biotechnology/medical biotechnology • bioprocessing and bioanalytics • nano(bio)technology and molecular diagnostics/therapy • cryo(bio)technology from cryoprocedures to cryomicroscopy • design and contruction of small, medium-sized and large biobanks • stem cell research and cell differentiation • tissue engineering and development of new in vitro culture systems • implants • theranostics • neuroprosthetics and technical implant components • (mobile) laboratory technologies, new concepts for wireless energy supply • medical and technical ultrasound applications • sonar technologies • autonomous deep-sea systems and acoustic imaging • sensor manufacturing/microsystems technology • telemetric data and energy transmission • multi-local sensors connected by communications technology • health information systems/medical networks Wissenschaftlicher Ansprechpartner: Prof. Dr. Heiko Zimmermann heiko.zimmermann@ibmt.fraunhofer.de Weitere Informationen: https://www.ibmt.fraunhofer.de https://www.spt.fraunhofer.de https://www.ebisc.org/ https://www.ebisc.org/files/EBiSC2-Press_release-Kick_off-V1.0.pdf?m=1552300583
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells

Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Summary
Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with epithelial-cell cancers and B cell lymphomas. An effective EBV vaccine is not available. We found that antibodies to the EBV glycoprotein gH/gL complex were the principal components in human plasma that neutralized infection of epithelial cells and that antibodies to gH/gL and gp42 contributed to B cell neutralization. Immunization of mice and nonhuman primates with nanoparticle vaccines that displayed components of the viral-fusion machinery EBV gH/gL or gH/gL/gp42 elicited antibodies that potently neutralized both epithelial-cell and B cell infection. Immune serum from nonhuman primates inhibited EBV-glycoprotein-mediated fusion of epithelial cells and B cells and targeted an epitope critical for virus-cell fusion. Therefore, unlike the leading EBV gp350 vaccine candidate, which only protects B cells from infection, these EBV nanoparticle vaccines elicit antibodies that inhibit the virus-fusion apparatus and provide cell-type-independent protection from virus infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways

Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Nephritis is a major cause of lupus morbidity. Putterman and colleagues use single-cell RNA sequencing on human renal and skin biopsies to describe the expression landscape associated with lupus nephritis.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Long-lived roundworms helped identify new anti-aging compounds among FDA approved drugs | EurekAlert! Science News

Long-lived roundworms helped identify new anti-aging compounds among FDA approved drugs | EurekAlert! Science News | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Researchers from Gero, Skolkovo Institute of Science and Technology (Skoltech), Moscow Institute of Physics and Technology (MIPT), and University of Arkansas for Medical Sciences (UAMS) collaborated to derive a transcriptomic signature of aging, which they confirmed using large transcriptomic...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Bradykinin Receptor B1 as a Therapeutic Target in Lupus Nephritis

Bradykinin Receptor B1 as a Therapeutic Target in Lupus Nephritis | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Using Bioss B1R and B2R antibodies, researchers from the University of Houston, Texas, and Tongji University School of Medicine, Shanghai, investigated whether antagonism of the bradykinin receptor B1R ameliorated lupus nephritis.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Understanding the mechanisms of reversal of type 2 diabetes

Understanding the mechanisms of reversal of type 2 diabetes | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Clinical and pathophysiological studies have shown type 2 diabetes to be a condition
mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas.
Within the liver, excess fat worsens hepatic responsiveness to insulin, leading to
increased glucose production.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis | Annals of the Rheumatic Diseases

T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis | Annals of the Rheumatic Diseases | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Disease-associated clones showed common features and high similarity between both autoimmune diseases. SLE displayed higher TCR heterogeneity than RA with several organ specific properties. Furthermore, the association between clonal expansion and the concentration of disease-associated clones with disease severity were identified, and pathogen-related TCRs were enriched in both diseases.

Conclusions These characteristics of the TCR repertoire, particularly the disease-associated clones, can potentially serve as biomarkers and provide novel insights for disease status and therapeutical targets in autoimmune diseases.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Retroviral UNC13D gene transfer restores cytotoxic activity of T cells derived from familial hemophagocytic lymphohistiocytosis type 3 patients in vitro | Human Gene Therapy

Retroviral UNC13D gene transfer restores cytotoxic activity of T cells derived from familial hemophagocytic lymphohistiocytosis type 3 patients in vitro | Human Gene Therapy | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Familial hemophagocytic lymphohistiocytosis (FHL) is a group of life-threatening, autosomal recessive disorders of severe hyperinflammation. FHL type 3 (FHL-3) accounts for about 30% of FHL cases. ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Visfatin as a therapeutic target for rheumatoid arthritis: Expert Opinion on Therapeutic Targets: Vol 0, No 0

Inhibition of visfatin has become an interesting therapeutic approach for RA pathology. Such a feat has already been attained in oncology using small molecule inhibitors, which suggest that a similar course of action would be worth pursuing in the RA context. Visfatin will become an important biomarker and therapeutic target for RA.

KEYWORDS: Autoimmunity, FK866, IL1β, IL6, inflammation, NAMPT, RA, RASF, TLRs, Visfatin
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previous...

Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previous... | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
A judicious analysis and comparison of studies on the immunogenicity of pneumococcal vaccine in patients with systemic lupus erythematosus (SLE)1–9 is hampered by wide heterogeneity in several factors, including differences in the immunoassays performed, cut-off levels used as serological...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Surprising research result: All immature cells can develop into stem cells

Surprising research result: All immature cells can develop into stem cells | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
A sensational new study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development. The study reveals that the destiny of intestinal cells is not predetermined, but instead determined ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Immunotherapies for autoimmune diseases

Immunotherapies for autoimmune diseases | Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights | Scoop.it
Autoimmune diseases should benefit from treatments that piggyback on the successes of cancer immunotherapies.
more...
No comment yet.